A study on predicting cases that would benefit from proton beam therapy in primary liver tumors of less than or equal to 5 cm based on the estimated incidence of hepatic toxicity

Uchinami, Yusuke; Katoh, Norio; Suzuki, Ryusuke; Kanehira, Takashi; Tamura, Masaya; Sugiyama, Takao; Matsuura, Tetsuya; Miyamoto, Naoki; Fujita, Yoshihiro; Koizumi, F.; Taguchi, Hiroshi; Yasuda, Kôichi; Nishioka, Kentaro; Yokota, Isao; Kobashi, Keiji; Aoyama, Hidefumi

doi:10.1016/j.ctro.2022.05.004

Cited by 3 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1) and plays a significant role in the vital metabolic functioning of the body these functions include removing waste products and foreign substances from the bloodstream, regulating blood sugar levels, and creating essential nutrients. During development, liver size increases with increasing age, averaging a 5 cm span at 5 years, and attaining an adult size average of about 8.6 cm (male and female) from age 15, with an average volume of 1624 cm 3 [11] and weighing about 1.5 kg. However, the size depends on several factors including age, sex, body size, shape, and to what extent the liver is healthy [ 13,14].…”

Section: Human Livermentioning

confidence: 99%

“…The Stopping power describes the energy loss per unit path length when charged particles, such as protons, propagate through matter [3,4,11,20]. Charged particles lose their energy mainly through collisions with atomic electrons of the traversed medium.…”

Section: Stopping Power and Rangementioning

confidence: 99%

“…Further studies and discussions are required to make proton therapy costeffective to address its use in several types of cancer and to maintain the quality of life of patients while achieving a high cure rate. Apart from the adverse effects of exposure to energetic particles due to carcinogenesis and degenerative disease, proton therapy in the treatment of cancer is a promising approach to curbing the growth of cancerous cells in the body [1,[7][8][9][10][11]. The damage (Bragg's peak) due to ionization and recoils in the target atoms during proton bombardment at a certain energy can be localized to destroy cancerous cells [4,11].…”

Section: Introductionmentioning

confidence: 99%

“…Apart from the adverse effects of exposure to energetic particles due to carcinogenesis and degenerative disease, proton therapy in the treatment of cancer is a promising approach to curbing the growth of cancerous cells in the body [1,[7][8][9][10][11]. The damage (Bragg's peak) due to ionization and recoils in the target atoms during proton bombardment at a certain energy can be localized to destroy cancerous cells [4,11]. Bragg peak is a distinct property of protons and when it reaches cancer tissues after penetrating through the normal tissues in the body, it releases an immense amount of radiation energy to kill the cancer cells and subsequently, it disappears instantly.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Proton Beam Therapy-Based Computation in the Treatment of Human Ovarian and Liver Cancer using Srim

Omojola,

Bamikole,

Ali

2023

LJSIR

View full text Add to dashboard Cite

Proton beam therapy is a promising technique used to cure various types of cancer diseases in the human body. This technique can selectively damage cancer cells while leaving surrounding cells unaffected thereby minimizing collateral damage to the healthy cells. The position and the width of the cancerous cells are determined to calculate the energy required to destroy the affected cells. The energy loss to the damaged cells and other body parts is calculated separately with high accuracy. Computational analysis indicates that proton beams with energies of 46 MeV, 47 MeV, and 48 MeV effectively destroy localized cancerous cells of the ovary from the epithelial cells to the more invasive cancerous growth while proton beam energy range of 50 MeV to 89 MeV should be considered for the treatment of liver cancer of both the periphery tumours and tumours in the hilum. Transport of ions in matter (TRIM) data shows that more than 80% of proton energy is given off during ion bombardment at Bragg’s peak, while the remaining percentage is lost by phonon production and by recoils.

show abstract

Section: Human Livermentioning

confidence: 99%

Section: Stopping Power and Rangementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Proton Beam Therapy-Based Computation in the Treatment of Human Ovarian and Liver Cancer using Srim

Omojola,

Bamikole,

Ali

2023

LJSIR

View full text Add to dashboard Cite

show abstract

Evaluation of short-term gastrointestinal motion and its impact on dosimetric parameters in stereotactic body radiation therapy for pancreatic cancer

Uchinami

Kanehira²,

Fujita³

et al. 2023

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

Study of hepatic toxicity in small liver tumors after photon or proton therapy based on factors predicting the benefits of proton

Uchinami

Katoh

Abo

et al. 2023

The British Journal of Radiology

View full text Add to dashboard Cite

Objectives: In a previous study of hepatic toxicity, the following three factors were identified to predict the benefits of proton beam therapy (PBT) for hepatocellular carcinomas (HCC) with a maximum diameter of ≤5 cm and Child-pugh grade A (CP-A): number of tumors (one vs ≥2), the location of tumors (hepatic hilum or others), and the sum of the diameters of lesions. The aim of this study is to analyze the association between these three factors and hepatic toxicity. Methods: We retrospectively reviewed patients of CP-A treated with PBT or photon stereotactic body radiotherapy (X-ray radiotherapy, XRT) for HCC ≤5 cm. For normal liver dose, the V5, V10, V20 (volumes receiving 5, 10, and 20 Gy at least), and the mean dose was evaluated. The albumin-bilirubin (ALBI) and CP score changes from the baseline were evaluated at 3 and 6 months after treatment. Results: In 89 patients (XRT: 48, PBT: 41), those with two or three (2-3) predictive factors were higher normal liver doses than with zero or one (0–1) factor. In the PBT group, the ALBI score worsened more in patients with 2–3 factors than those with 0–1 factor, at 3 months (median 0.26 vs 0.02, p = 0.032) and at 6 months (median: 0.35 vs 0.10, p = 0.009). The ALBI score change in the XRT group and CP score change in either modality were not significantly different in the number of predictive factors. Conclusions: The predictive factor numbers predicted the ALBI score change in PBT but not in XRT. Advances in knowledge: This study suggest that the number of predictive factors previously identified (0-1 vs 2-3) were significantly associated with dosimetric parameters of the normal liver in both modalities. In the proton group, the number of predictive factors was associated with a worsening ALBI score at 3 and 6 months, but these associations were not found in the photon SBRT group.

show abstract

A study on predicting cases that would benefit from proton beam therapy in primary liver tumors of less than or equal to 5 cm based on the estimated incidence of hepatic toxicity

Cited by 3 publications

References 30 publications

Proton Beam Therapy-Based Computation in the Treatment of Human Ovarian and Liver Cancer using Srim

Proton Beam Therapy-Based Computation in the Treatment of Human Ovarian and Liver Cancer using Srim

Evaluation of short-term gastrointestinal motion and its impact on dosimetric parameters in stereotactic body radiation therapy for pancreatic cancer

Study of hepatic toxicity in small liver tumors after photon or proton therapy based on factors predicting the benefits of proton

Contact Info

Product

Resources

About